This is AWESOME news and confirms what I and a few others have been saying on this forum for months now.... that ARG-007 is a very promising candidate for therapeutic use in alzheimer's patients. Great to see the company exploring this absolutely massive market for which there is no decent treatment.
Ann: Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers, page-10
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
83.5¢ |
Change
-0.025(2.91%) |
Mkt cap ! $103.2M | |||
| Open | High | Low | Value | Volume |
| 87.0¢ | 87.0¢ | 82.0¢ | $107.3K | 128.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6891 | 83.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 86.0¢ | 7770 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AGN (ASX) Chart |